Latest Conference Coverage


Solriamfetol Shows Therapeutic Benefits on Neuropsychological Outcomes in Excessive Daytime Sleepiness

Solriamfetol Shows Therapeutic Benefits on Neuropsychological Outcomes in Excessive Daytime Sleepiness

June 9th 2025

New research reveals solriamfetol significantly enhances neuropsychological outcomes in patients with obstructive sleep apnea and excessive daytime sleepiness.


Negative Study Findings Further Question Effectiveness of Transcranial Direct Stimulation to Treat Insomnia

Negative Study Findings Further Question Effectiveness of Transcranial Direct Stimulation to Treat Insomnia

June 9th 2025

Recent research reveals that transcranial direct current stimulation (tDCS) shows no significant benefits for insomnia, highlighting the need for larger studies.


Gita Gupta, MD, MS  (Credit: LGS Foundation)

Wearable Devices Preferred Over Traditional Sleep Studies When Monitoring Ambulatory Sleep in Pediatric Lennox-Gastaut Syndrome

June 9th 2025

A newly presented study at SLEEP 2025 explored the practicality of various methods, such as the Apple Watch and polysomnogram, for assessing sleep in pediatric patients with Lennox-Gastaut syndrome.


REFRESH Study to Test Real-World Clinical Effectiveness of Once-Nightly Sodium Oxybate

REFRESH Study to Test Real-World Clinical Effectiveness of Once-Nightly Sodium Oxybate

June 8th 2025

A new study evaluates the effectiveness and safety of once-nightly sodium oxybate for narcolepsy, aiming to enhance patient treatment experiences.


Samelisant Significantly Reduces Excessive Daytime Sleepiness in Phase 2 Narcolepsy Study

Samelisant Significantly Reduces Excessive Daytime Sleepiness in Phase 2 Narcolepsy Study

June 8th 2025

A phase 2 study shows samelisant significantly reduces excessive daytime sleepiness in narcolepsy, paving the way for further research and development.


Sam Hooshmand, DO  (Credit: Medical College of Wisconsin)

Clinical Insight on Challenges and Evolving Strategies in Advanced Multiple Sclerosis Care

June 7th 2025

Sam Hooshmand, DO, assistant professor of neurology at the Medical College of Wisconsin, discussed the complexities of defining, diagnosing, and managing advanced MS.


Kathy Zackowski, PhD, OTR

Expanding the Scope of Wellness Research in Multiple Sclerosis: Kathy Zackowski, PhD, OTR

June 6th 2025

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]


Ahmed Abdelhak, MD  (Credit: UCSF)

Conversations on Biomarker Use in Multiple Sclerosis Remyelination Research

June 6th 2025

Ahmed Abdelhak, MD, assistant professor of neurology at the UCSF, discussed the evolving landscape of biomarkers in multiple sclerosis and their potential to transform remyelination approaches.


 Sumaira Ahmed

Investigating Treatment Differences of Off-Label and Marketed Therapies for NMOSD: Sumaira Ahmed

June 5th 2025

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]


Reactivating Muscle Stem Cells in DMD: The Science Behind SAT-3247

Reactivating Muscle Stem Cells in DMD: The Science Behind SAT-3247

June 5th 2025

Phil Lambert, PhD, chief scientific officer at Satellos Bioscience, discusses the rationale and early clinical progress of SAT-3247, a novel regenerative therapy targeting muscle stem cells in Duchenne muscular dystrophy.


Tiffany Malone, MSW, MSCS

Addressing Social Isolation and Feelings of Loneliness in Patients With MS: Tiffany Malone, MSW, MSCS

June 5th 2025

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health highlighted the significant impact of loneliness in individuals with multiple sclerosis. [WATCH TIME: 6 minutes]


Ahmed Abdelhak, MD

Emerging Biomarkers for Monitoring Remyelination in Multiple Sclerosis: Ahmed Abdelhak, MD

June 4th 2025

The assistant professor of neurology at the University of California, San Francisco discussed current advancements and ongoing challenges in identifying biomarkers to accurately monitor remyelination in MS clinical trials. [WATCH TIME: 5 minutes]


Evaluating Risk: Clarifying the Safety Data Behind Efgartigimod

Evaluating Risk: Clarifying the Safety Data Behind Efgartigimod

June 4th 2025

Josh Bryson, PhD, head of Medical Affairs at Argenx, discussed the safety profile of efgartigimod in light of recent FAERS-based infection data and offered clinical context for patient care.


Smathorn Thakolwiboon, MD

A Case-Based Overview of Treatment Strategies for Relapse Prevention in MOGAD: Smathorn Thakolwiboon, MD

June 4th 2025

The assistant professor of neurology at Mayo Clinic College of Medicine and Science outlined a case of myelin oligodendrocyte glycoprotein antibody-associated disease from diagnosis to long-term management. [WATCH TIME: 5 minutes]


NeuroVoices: Kathy Zackowski, PhD, OTR, on Promoting Psychosocial Wellness Research in MS Care

NeuroVoices: Kathy Zackowski, PhD, OTR, on Promoting Psychosocial Wellness Research in MS Care

June 4th 2025

The associate vice president of research at National MS Society talked about the need for evidence-based wellness strategies in multiple sclerosis, particularly focusing on psychosocial interventions.


Mahsa Ghajarzadeh, MD, PhD  (Credit: LinkedIn)

Meta-Analysis Reveals Cognitive Behavioral Therapy Ineffective for MS-Related Fatigue

June 3rd 2025

Findings from a late-breaking poster presented at CMSC 2025 suggest that CBT does not improve fatigue severity or impact in patients with multiple sclerosis.


Gabrielle Macaron, MD

Individualizing Disease-Modifying Therapy Selection in Newly Diagnosed MS: Gabrielle Macaron, MD

June 3rd 2025

The assistant professor in the Department of Neuroscience at Université de Montréal discussed key clinical factors influencing DMT selection in patients newly diagnosed with multiple sclerosis. [WATCH TIME: 5 minutes]


OPTIMUM Phase 3 Extension Further Highlights Sustained Efficacy, Safety of Ponesimod

OPTIMUM Phase 3 Extension Further Highlights Sustained Efficacy, Safety of Ponesimod

June 3rd 2025

New long-term data reveals ponesimod's effectiveness in reducing relapses and MRI lesions in relapsing multiple sclerosis patients, ensuring safety over 8.2 years.


Neurologists Support DMT Use in Older Patients With Multiple Sclerosis, Survey Shows

Neurologists Support DMT Use in Older Patients With Multiple Sclerosis, Survey Shows

June 2nd 2025

Neurologists advocate for personalized treatment approaches in older MS patients, emphasizing the importance of individual assessment over age-based rules for DMT discontinuation.


E. Ann Yeh, MD

Treatment and Diagnosis of MOG-Associated Disorders in Pediatric vs Adult: E. Ann Yeh, MD

June 2nd 2025

The professor of pediatrics in neurology at the University of Toronto discussed differences in disease course, treatment strategy, and trial challenges of MOG-associated disorders in pediatric versus adult patients. [WATCH TIME: 5 minutes]


BTK Inhibitor Fenebrutinib Demonstrates Long-Term Suppression of MS Activity in Open-Label Extension

BTK Inhibitor Fenebrutinib Demonstrates Long-Term Suppression of MS Activity in Open-Label Extension

June 2nd 2025

Fenebrutinib shows promising results in reducing relapse rates and disability progression in relapsing multiple sclerosis patients over two years.


Michael Robers, MD, MS

Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS

June 2nd 2025

The assistant professor of neurology at Barrow Neurological Institute talked about the lack of public awareness for hypertension among individuals with MS despite many meeting diagnostic criteria. [WATCH TIME: 6 minutes]


MS Therapy Cladribine Remains Effective in Patients With Suboptimal Response to Prior Injectable DMT

MS Therapy Cladribine Remains Effective in Patients With Suboptimal Response to Prior Injectable DMT

June 1st 2025

Cladribine shows promising results in reducing relapse rates for patients with relapsing multiple sclerosis after inadequate response to injectable therapies.


Mary R. Rensel, MD

Starting Comprehensive Multiple Sclerosis Care at Initial Diagnosis: Mary R. Rensel, MD, FAAN, ABIHM

May 31st 2025

The associate professor of medicine at the Cleveland Clinic Lerner College of Medicine highlighted the importance of early, multidisciplinary intervention for patients with multiple sclerosis. [WATCH TIME: 3 minutes]


CMSC Live: 2025 Annual Meeting Day 3

CMSC Live: 2025 Annual Meeting Day 3

May 31st 2025

Host Jeffrey Wilken, PhD, chats with Riley Bove, MD, about the third day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.


Riley Bove, MD  (Credit: University of California, San Francisco)

Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates

May 30th 2025

A newly presented analysis of data from the Novartis Global Safety Database and the PRIM study assessed pregnancy and infant outcomes in women with multiple sclerosis treated with ofatumumab.


Celia Oreja-Guevara, MD, PhD

Identifying and Treating Progression in MS Beyond Relapses: Celia Oreja-Guevara, MD, PhD

May 30th 2025

The vice chair of neurology at the Hospital Clínico San Carlos in Madrid highlighted the growing importance of detecting and managing progression in multiple sclerosis, particularly PIRA. [WATCH TIME: 6 minutes]


Fumarates Lead to Lower Infection-Related Healthcare Resource Utilization Relative to Anti-CD20s

Fumarates Lead to Lower Infection-Related Healthcare Resource Utilization Relative to Anti-CD20s

May 30th 2025

A study reveals long-term fumarate therapy significantly reduces infection-related healthcare utilization in multiple sclerosis patients compared to anti-CD20 treatments.

© 2025 MJH Life Sciences

All rights reserved.